1. Home
  2. IKT vs BCIC Comparison

IKT vs BCIC Comparison

Compare IKT & BCIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.66

Market Cap

181.9M

Sector

Health Care

ML Signal

HOLD

BCIC

BCP Investment Corporation

N/A

Current Price

$11.81

Market Cap

159.5M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
IKT
BCIC
Founded
2008
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
181.9M
159.5M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
IKT
BCIC
Price
$1.66
$11.81
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
499.5K
81.5K
Earning Date
11-14-2025
11-06-2025
Dividend Yield
N/A
16.11%
EPS Growth
N/A
330.32
EPS
N/A
1.64
Revenue
N/A
$58,080,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$12.00
P/E Ratio
N/A
$7.19
Revenue Growth
N/A
N/A
52 Week Low
$1.33
$11.12
52 Week High
$3.49
$17.51

Technical Indicators

Market Signals
Indicator
IKT
BCIC
Relative Strength Index (RSI) 57.62 N/A
Support Level $1.52 N/A
Resistance Level $1.67 N/A
Average True Range (ATR) 0.11 0.00
MACD 0.02 0.00
Stochastic Oscillator 65.91 0.00

Price Performance

Historical Comparison
IKT
BCIC

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

About BCIC BCP Investment Corporation

BCP Investment Corp is a closed-end, externally managed, non-diversified management investment company. The company invests in performing, well- established middle market businesses that operate across a wide range of industries. It employs fundamental credit analysis, targeting investments in businesses with relatively low levels of cyclicality and operating risk.

Share on Social Networks: